Anda Vlad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anda Vlad has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Francesmary Modugno
Department of Obstetrics, Gynecology, and Reproductive Sciences University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
53 shared publications - Ronald J. Buckanovich
Magee-Womens Research Institute, Pittsburgh, PA 15213, USA
48 shared publications - Alexander J. Cole
Centenary Institute and Faculty of Medicine and Health, The University of Sydney
47 shared publications - Ece Gumusoglu-Acar
Istanbul University
47 shared publications - Jaynish S. Shah
Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St. Leonards, New South Wales, Australia
47 shared publications - Maya G. Bello
Department of Internal Medicine and Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania
47 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 3. The effect of FST or taxol treatment ovarian cancer proliferation and FST secretion, and the ability of a FST neutralization antibody to inhibit FST's effect on proliferation. A. PT340 and PT412 cells were treated with 200 ng/mL FST for 72h before cell counts were performed. B (i) IHC images and (ii) FST+ cell bodies in OVSAHO tumor xenografts treated with or without taxol and stained with both Ki67 (Forangi Blue) and FST (Fast Red). C. Titer of the ability of the anti-FST neutralizing antibody to inhibit the effect of FST on cell growth.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 3. The effect of FST or taxol treatment ovarian cancer proliferation and FST secretion, and the ability of a FST neutralization antibody to inhibit FST's effect on proliferation. A. PT340 and PT412 cells were treated with 200 ng/mL FST for 72h before cell counts were performed. B (i) IHC images and (ii) FST+ cell bodies in OVSAHO tumor xenografts treated with or without taxol and stained with both Ki67 (Forangi Blue) and FST (Fast Red). C. Titer of the ability of the anti-FST neutralizing antibody to inhibit the effect of FST on cell growth.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 5. Schematic of FST CRISPR KO guides and in vivo experiment. A. Binding of the two commercially available FST CRISPR guides to FST to mediate KO. B. Mice were injected with SKOV3 cells expressing FST sgRNA #2. Mice were then treated 3 times with 10mg/kg Taxol intraperitoneal Paclitaxel at days 7, 14 and 21. C Dissection of control mice presenting with multiple metastases and an FST-KO mice which showed no residual disease. White arrows point to sites of disease.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 5. Schematic of FST CRISPR KO guides and in vivo experiment. A. Binding of the two commercially available FST CRISPR guides to FST to mediate KO. B. Mice were injected with SKOV3 cells expressing FST sgRNA #2. Mice were then treated 3 times with 10mg/kg Taxol intraperitoneal Paclitaxel at days 7, 14 and 21. C Dissection of control mice presenting with multiple metastases and an FST-KO mice which showed no residual disease. White arrows point to sites of disease.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 4. The effect of ATF2 siRNA on gene expression and PT340 FST induced chemoresistance. A. Schematic detailing the transwell experiments. CellTrace Violet cells were sorted for rapidly dividing (Dim) or quiescent cells (Bright) which were then plated in transwell chambers either as Dim:Dim or Bright:Dim. Cells were untreated or treated with taxol alone or in combination with IgG or anti-FST antibody. Cell counts were performed on the dim cells and data was expressed as fold chnage. B. Relative ATF2 gene expression of PT412 and PT340 treated with scrambled siRNA or two independent ATF2 siRNAs (ATF2 siRNA #1 and #2). C. Viable cell number of PT340 cells treated with control scrambled siRNA or knocked down with ATF2 siRNA and treated with cisplatin +/- FST. *P<0.05, ns = not significant.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 4. The effect of ATF2 siRNA on gene expression and PT340 FST induced chemoresistance. A. Schematic detailing the transwell experiments. CellTrace Violet cells were sorted for rapidly dividing (Dim) or quiescent cells (Bright) which were then plated in transwell chambers either as Dim:Dim or Bright:Dim. Cells were untreated or treated with taxol alone or in combination with IgG or anti-FST antibody. Cell counts were performed on the dim cells and data was expressed as fold chnage. B. Relative ATF2 gene expression of PT412 and PT340 treated with scrambled siRNA or two independent ATF2 siRNAs (ATF2 siRNA #1 and #2). C. Viable cell number of PT340 cells treated with control scrambled siRNA or knocked down with ATF2 siRNA and treated with cisplatin +/- FST. *P<0.05, ns = not significant.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 2. RNA-seq analysis. A. Schematic of the RNA-seq experimental design. B. Waterfall plot of RNA-seq data showing the 141 genes which were DE at all time points compared to luciferase control in HEY1 and SKOV3 cell lines. C. Unsupervised clustering analysis of the 141 DE genes. D. Box plots demonstrating MYC expression following NFATC4 activation. E. STRING analysis of the 141 DE genes.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 2. RNA-seq analysis. A. Schematic of the RNA-seq experimental design. B. Waterfall plot of RNA-seq data showing the 141 genes which were DE at all time points compared to luciferase control in HEY1 and SKOV3 cell lines. C. Unsupervised clustering analysis of the 141 DE genes. D. Box plots demonstrating MYC expression following NFATC4 activation. E. STRING analysis of the 141 DE genes.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Table 1. Primers used in this study.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Table 1. Primers used in this study.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 1. Histological analysis of PT340 cell line. PT340 cells were injected into NSG mice, and the resulting tumors were harvested for histological analysis, H&E staining showed features of Clear Cell Ovarian Carcinoma.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Supplementary Figure 1. Histological analysis of PT340 cell line. PT340 cells were injected into NSG mice, and the resulting tumors were harvested for histological analysis, H&E staining showed features of Clear Cell Ovarian Carcinoma.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Purpose:We recently reported that the transcription factor NFATC4, in response to chemotherapy, drives cellular quiescence to increase ovarian cancer chemoresistance. The goal of this work was to better understand the mechanisms of NFATC4-driven ovarian cancer chemoresistance.Experimental Design:We used RNA sequencing to identify NFATC4-mediated differential gene expression. CRISPR-Cas9 and FST (follistatin)-neutralizing antibodies were used to assess impact of loss of FST function on cell proliferation and chemoresistance. ELISA was used to quantify FST induction in patient samples and in vitro in response to chemotherapy.Results:We found that NFATC4 upregulates FST mRNA and protein expression predominantly in quiescent cells and FST is further upregulated following chemotherapy treatment. FST acts in at least a paracrine manner to induce a p-ATF2–dependent quiescent phenotype and chemoresistance in non-quiescent cells. Consistent with this, CRISPR knockout (KO) of FST in ovarian cancer cells or antibody-mediated neutralization of FST sensitizes ovarian cancer cells to chemotherapy treatment. Similarly, CRISPR KO of FST in tumors increased chemotherapy-mediated tumor eradication in an otherwise chemotherapy-resistant tumor model. Suggesting a role for FST in chemoresistance in patients, FST protein in the abdominal fluid of patients with ovarian cancer significantly increases within 24 hours of chemotherapy exposure. FST levels decline to baseline levels in patients no longer receiving chemotherapy with no evidence of disease. Furthermore, elevated FST expression in patient tumors is correlated with poor progression-free, post–progression-free, and overall survival.Conclusions:FST is a novel therapeutic target to improve ovarian cancer response to chemotherapy and potentially reduce recurrence rates.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy
Purpose:We recently reported that the transcription factor NFATC4, in response to chemotherapy, drives cellular quiescence to increase ovarian cancer chemoresistance. The goal of this work was to better understand the mechanisms of NFATC4-driven ovarian cancer chemoresistance.Experimental Design:We used RNA sequencing to identify NFATC4-mediated differential gene expression. CRISPR-Cas9 and FST (follistatin)-neutralizing antibodies were used to assess impact of loss of FST function on cell proliferation and chemoresistance. ELISA was used to quantify FST induction in patient samples and in vitro in response to chemotherapy.Results:We found that NFATC4 upregulates FST mRNA and protein expression predominantly in quiescent cells and FST is further upregulated following chemotherapy treatment. FST acts in at least a paracrine manner to induce a p-ATF2–dependent quiescent phenotype and chemoresistance in non-quiescent cells. Consistent with this, CRISPR knockout (KO) of FST in ovarian cancer cells or antibody-mediated neutralization of FST sensitizes ovarian cancer cells to chemotherapy treatment. Similarly, CRISPR KO of FST in tumors increased chemotherapy-mediated tumor eradication in an otherwise chemotherapy-resistant tumor model. Suggesting a role for FST in chemoresistance in patients, FST protein in the abdominal fluid of patients with ovarian cancer significantly increases within 24 hours of chemotherapy exposure. FST levels decline to baseline levels in patients no longer receiving chemotherapy with no evidence of disease. Furthermore, elevated FST expression in patient tumors is correlated with poor progression-free, post–progression-free, and overall survival.Conclusions:FST is a novel therapeutic target to improve ovarian cancer response to chemotherapy and potentially reduce recurrence rates.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Supplementary figures and table
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Supplementary figures and table
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells (enMSC) characterized by loss of CD10 expression that specifically support OCCC growth. RNA sequencing identified alterations in iron export in CD10-negative enMSCs and reciprocal changes in metal transport in cocultured OCCC cells. CD10-negative enMSCs exhibited elevated expression of iron export proteins hephaestin and ferroportin and donate iron to associated OCCCs, functionally increasing the levels of labile intracellular iron. Iron is necessary for OCCC growth, and CD10-negative enMSCs prevented the growth inhibitory effects of iron chelation. In addition, enMSC-mediated increases in OCCC iron resulted in a unique sensitivity to ferroptosis. In vitro and in vivo, treatment with the ferroptosis inducer erastin resulted in significant death of cancer cells grown with CD10-negative enMSCs. Collectively, this work describes a novel mechanism of stromal-mediated tumor support via iron donation. This work also defines an important role of endometriosis-associated MSCs in supporting OCCC growth and identifies a critical therapeutic vulnerability of OCCC to ferroptosis based on stromal phenotype.Significance:Endometriosis-derived mesenchymal stem cells support ovarian clear cell carcinoma via iron donation necessary for cancer growth, which also confers sensitivity to ferroptosis-inducing therapy.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Endometriosis-Associated Mesenchymal Stem Cells Support Ovarian Clear Cell Carcinoma through Iron Regulation
Ovarian clear cell carcinoma (OCCC) is a deadly and treatment-resistant cancer, which arises within the unique microenvironment of endometriosis. In this study, we identified a subset of endometriosis-derived mesenchymal stem cells (enMSC) characterized by loss of CD10 expression that specifically support OCCC growth. RNA sequencing identified alterations in iron export in CD10-negative enMSCs and reciprocal changes in metal transport in cocultured OCCC cells. CD10-negative enMSCs exhibited elevated expression of iron export proteins hephaestin and ferroportin and donate iron to associated OCCCs, functionally increasing the levels of labile intracellular iron. Iron is necessary for OCCC growth, and CD10-negative enMSCs prevented the growth inhibitory effects of iron chelation. In addition, enMSC-mediated increases in OCCC iron resulted in a unique sensitivity to ferroptosis. In vitro and in vivo, treatment with the ferroptosis inducer erastin resulted in significant death of cancer cells grown with CD10-negative enMSCs. Collectively, this work describes a novel mechanism of stromal-mediated tumor support via iron donation. This work also defines an important role of endometriosis-associated MSCs in supporting OCCC growth and identifies a critical therapeutic vulnerability of OCCC to ferroptosis based on stromal phenotype.Significance:Endometriosis-derived mesenchymal stem cells support ovarian clear cell carcinoma via iron donation necessary for cancer growth, which also confers sensitivity to ferroptosis-inducing therapy.
- Open Access
- 11 July 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (7)
Novel murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer
Preclinical modeling of epithelial ovarian cancer in immune competent mice progressing to orthotopic, spontaneous tumors is challenging, requiring multiple genetic modifications in the host. Transplantable models using cell lines are easier to implement, given that they reproduce the key disease characteristics. To create new in vivo ovarian tumor models, we have generated a total of 28 murine ovarian cancer cell lines with distinct genetic traits such as deletion of Trp53, activation of KrasG12D, deletion of Pten or KrasG12D/Pten−/- combination. Two distinct Trp53 null cell lines recapitulate high grade serous histology when orthotopically injected in immune competent, syngeneic hosts. Cells with Pten deletion trigger high grade endometrioid tumors, and cells with dual KrasG12D activation and Pten deletion model carcinosarcoma. The cells express different tumor antigens, secrete varying levels of cytokines and chemokines, and trigger tumors with diverse inflammation profiles and various intratumoral T and B lymphocyte infiltration patterns. RNAseq data from 16 cell lines reveal the gene expression profile across distinct models with different histotypes. This versatile collection of murine cell lines supports translationally relevant studies in ovarian cancer.
- 11 July 2025
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 18 (7)
Open AccessNovel murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer
Preclinical modeling of epithelial ovarian cancer in immune competent mice progressing to orthotopic, spontaneous tumors is challenging, requiring multiple genetic modifications in the host. Transplantable models using cell lines are easier to implement, given that they reproduce the key disease characteristics. To create new in vivo ovarian tumor models, we have generated a total of 28 murine ovarian cancer cell lines with distinct genetic traits such as deletion of Trp53, activation of KrasG12D, deletion of Pten or KrasG12D/Pten−/- combination. Two distinct Trp53 null cell lines recapitulate high grade serous histology when orthotopically injected in immune competent, syngeneic hosts. Cells with Pten deletion trigger high grade endometrioid tumors, and cells with dual KrasG12D activation and Pten deletion model carcinosarcoma. The cells express different tumor antigens, secrete varying levels of cytokines and chemokines, and trigger tumors with diverse inflammation profiles and various intratumoral T and B lymphocyte infiltration patterns. RNAseq data from 16 cell lines reveal the gene expression profile across distinct models with different histotypes. This versatile collection of murine cell lines supports translationally relevant studies in ovarian cancer.